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Abstract
Background: Androgen deprivation therapy (ADT) remains a primary treatment for localized prostate cancer (PCa)
even though there is no evidence that its use is beneficial in the absence of curative treatment.
Methods: Men aged ≥70 years (n = 16,534) diagnosed with localized PCa from 1985 to 2014 and managed either
with primary observation or ADT in the absence of curative treatment were included. The cases were identified
from the population-based Finnish Cancer Registry. We estimated the standardized mortality ratios (SMR) for overall
mortality by treatment group. We determined the relative risk (RR) of PCa-specific mortality (PCSM) and other-cause
mortality between the two treatment groups. Survival was determined using the life table method. Two age groups
(70–79 years and≥ 80 years) and three calendar time cohorts (1985–1994, 1995–2004, and 2005–2014) were compared
following adjustment of propensity score matching between the treatment groups with four covariates (age, year of
diagnosis, educational level, and hospital district). Follow-up continued until death or until December 31, 2015.
Results: Patients in the observation group had lower overall SMRs than those in the ADT group in both age cohorts
over the entire study period. PCSM was higher in men aged 70–79 years undergoing primary ADT compared to those
managed by observation only (RR: 1.70, 95% confidence interval [CI]: 1.29–2.23 [1985–1994]; RR 1.55, 95% CI: 1.35–1.84
[1995–2004]; and RR 2.71, 95% CI: 2.08–3.53 [2005–2014]); p = 0.005 for periodic trend. A similar trend over time was
also observed in men aged > 80 years; (p for age–period interaction = 0.237). Overall survival was also higher among
men in their 70’s managed by observation compared to those undergoing ADT.
Conclusions: Primary ADT within four months period from diagnosis is not associated with improved long-term
overall survival or decreased PCSM compared to primary conservative management for men with localized PCa.
However, this observational study’s conclusions should be weighted with confounding factors related to cancer
aggressiveness and comorbidities.
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Background
Androgen deprivation therapy (ADT) has been the
cornerstone of treatment for locally advanced and meta-
static (M+) prostate cancer (PCa) since the 1940s [1].
Immediate ADT or ADT combined with docetaxel or
abiraterone acetate is the current treatment of choice for
M+ PCa [2]. However, the use of ADT increased sharply
between 1989 and 2001 in the USA despite the fact that
≤5% of patients with newly diagnosed PCa have distant
metastases at first presentation compared with 20–25%
≥20 years ago [3, 4]. While the increased use of ADT is
partly accounted for by the uptake of neoadjuvant and
adjuvant treatment along with radiation therapy, it is
primarily elucidated by ADT for localized disease, espe-
cially for elderly patients [5]. Thus, ADT is commonly
used to treat localized PCa although it has not been
shown to improve survival [6].
The risk of metastases or death from conservatively
managed clinical stage T1/T2 cancers was estimated in a
meta-analysis of six studies from the era prior to
prostate-specific antigen (PSA) [7]. The risk of metasta-
sis at 10 years was found to be 19, 42, and 74% for well-
differentiated, moderately differentiated, and poorly dif-
ferentiated tumors, respectively [7]. Similarly, the long-
term clinical outcomes of localized PCa without initial
treatment with curative intent during the PSA era were
assessed [8]. Thirty per cent of the patients died of PCa
and 30% of other causes within a 12-year period [8]. A
landmark Swedish study demonstrated a benign course
of well- or intermediately differentiated PCa in the ab-
sence of initial treatment with curative intent [9]. Thus,
the clinical course of localized high-risk PCa can be pro-
gressive, but the majority of cancers are indolent and
slow to progress [2]. According to current guidelines,
observation with the option of later treatment in the
case of disease progression (i.e., watchful waiting) is rec-
ommended for localized and locally advanced PCa in
elderly patients with competing comorbidities.
The objective of this observational study was to inves-
tigate mortality in elderly PCa patients primarily man-
aged with ADT or observation only during long follow-
ups in Finland.
Methods
Study population
The Finnish Cancer Registry is a nationwide population-
based register of all incident cancer cases diagnosed in
Finland since 1953. The health care personnel in hospi-
tals, outpatient clinics, and healthcare facilities are obli-
gated to notify of new cases. Additionally, pathology
notifications are received from all histopathological la-
boratories in Finland. The registry coverage is estimated
at 99% for male genital cancers [10]. The spreading into
localized, locally advanced, or metastatic are classified by
tumor size, regional node involvement, and presence of
metastasis for cases covered by the Finnish Cancer
Registry.
The Finnish Cancer Registry data can be linked with
the population register center database for dates of death
or emigration and causes of death and education levels
from Statistics Finland.
We identified all PCa patients aged 70 years or older at
diagnosis with localized cancer (clinical stage T1/T2)
from 1985 to 2014 and managed by primary ADT or ob-
servation in the absence of radical treatment with cura-
tive intent (Table 1). Of the total patients identified (n =
16,534), 11,572 were aged 70–79 years and 4962 were ≥
80. Within four months of diagnosis, the primary treat-
ment was ADT (ADT group n = 9704), while 6830 re-
ceived no treatment (observation group) (Table 1). The
regional data included 22 hospital districts taking care of
specialized care. The survival rates of the patients were
compared by age and treatment group over three pe-
riods (1985–1994, 1995–2004, and 2005–2014).
Statistical analysis
Overall survival was evaluated using the life table
method [11]. The Poisson regression model was used to
quantify differences in patient mortality between the de-
fined groups. The results were reported as relative risk
(RR) of PCa-specific mortality (PCSM) and mortality
due to causes other than PCa. We also estimated the
standardized mortality ratio (SMR) for overall mortality
among the patients. The SMR is estimated as the ratio
of observed and expected numbers of deaths. The latter
was derived from the mortality rates of the male popula-
tion in Finland stratified by age (1-year intervals), calen-
dar year and education. We used a nearest neighbor
matching with a logistic regression–based propensity
score [12] to identify a cohort of 5715 paired patients. In
the logistic regression, the probability of a given treat-
ment was modeled as a function of age and calendar
period (in 5-year groups), education, and hospital dis-
trict. Interactions between calendar period and each of
the covariates were also included in the model. Statis-
tical analysis was performed with R (version 3.2.3) using
the packages popEpi [13] and MatchIt [14].
The study protocol was approved by the institutional
review board of the Hospital District of Southwest
Finland. The National Institute for Health and Welfare
(Finland) approved access to the registry data (study
number 182/5.05.00/2015). Statistics Finland approved
access to the data on the cause of death (study number
TK-53-86-17).
Results
The stage distribution of all prostate cancer patients
from 1985 to 2014 (n = 95,959) in Finland is shown in
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Supplementary Table 1. Approximately half of the pa-
tients were classified as having localized PCa. The pro-
portion of metastatic disease decreased from 28 to 17%
between the periods 1985–1994 and 2005–2014. How-
ever, the PCa stage was missing in nearly one-third of
the patients over the study period (Supplementary
Table 1). In this study, we included only PCa patients
aged 70 years or older at diagnosis who received primary
treatment with ADT or no treatment within four
months of diagnosis (Table 1).
SMR analysis showed that overall mortality was lower
in the observation group than in the ADT group in all
three time periods. However, a declining trend in SMR
over time was seen in both groups. Furthermore, over
the most recent period (2005–2014), patients in both
age cohorts had lower overall mortality than the general
male population in Finland (SMR: 0.93, 95% CI: 0.88–
0.98) (Table 2). Propensity score matching did not
change any of these results.
In both age cohorts, we observed higher PCSM in pa-
tients undergoing primary ADT compared to those
managed by observation only (Table 3). The relative risk
of prostate cancer mortality increased significantly over
time in the ADT group compared to the observation
group (p for trend = 0.05). On the other hand, the risk of
death from causes other than PCa decreased over time
in patients aged 70–79 years undergoing primary ADT
compared to those managed by observation only, but the
same was not true in patients aged 80 years or older
(Table 3).
Overall survival of PCa patients aged 70–79 years was
higher in the observation group than in the ADT group
throughout the study period. However, a rising trend
was observed in both treatment groups. Among patients
over 80 years of age, overall survival improved over time
in both treatment groups with no significant differences
between them until the most recent period (from 2005
to 2014), when overall survival in the observation group
was higher than in the ADT group (Fig. 1). The results
remained similar after propensity score matching.
Discussion
In this population-based study, we investigated whether
the survival and mortality outcomes in elderly male
Table 1 Study population of prostate cancer patients
All patients
ADT Observation
Variable N % N %
Age at diagnosis
70–74 3096 31.9 2850 41.7
75–79 3411 35.2 2215 32.4
80–84 2170 22.4 1227 18.0
85–89 832 8.6 438 6.4
> 90 195 2.0 100 1.5
Total 9704 100 6830 100
Year of diagnosis
1985–1989 785 8.1 208 3.0
1990–1994 1197 12.3 337 4.9
1995–1999 1724 17.8 797 11.7
2000–2004 2159 22.2 1313 19.2
2005–2009 2280 23.5 2194 32.1
2010–2014 1559 16.1 1981 29.0
Total 9704 100 6830 100
Education level
Basic 6920 71.3 4421 64.7
Secondary 1325 13.7 1074 15.7
High 1459 15.0 1335 19.5
Total 9704 100 6830 100
Hospital district
Uusimaa 932 9.6 786 11.5
Helsinki 812 8.4 698 10.2
Varsinais-Suomi 835 8.6 628 9.2
Satakunta 500 5.2 281 4.1
Kanta-Hame 471 4.9 322 4.7
Pirkanmaa 1187 12.2 614 9.0
Paijat-Hame 668 6.9 304 4.5
Kymenlaakso 433 4.5 182 2.7
Etela-Karjala 321 3.3 179 2.6
Etela-Savo 158 1.6 102 1.5
Ita-Savo 76 0.8 64 0.9
Pohjois-Karjala 149 1.5 178 2.6
Pohjois-Savo 466 4.8 403 5.9
Keski-Suomi 374 3.9 557 8.2
Etela-Pohjanmaa 522 5.4 386 5.7
Vaasa 285 2.9 182 2.7
Keski-Pohjanmaa 136 1.4 128 1.9
Pohjois-Pohjanmaa 610 6.3 372 5.4
Kainuu 265 2.7 99 1.4
Lansi-Pohja 280 2.9 132 1.9
Lappi 190 2.0 177 2.6
Table 1 Study population of prostate cancer patients
(Continued)
All patients
ADT Observation
Variable N % N %
Åland 34 0.4 56 0.8
Total 9704 100 6830 100
ADT androgen deprivation therapy, N number
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patients (aged ≥70 years) with localized PCa is different
between those managed by primary observation and
those undergoing primary ADT over a long period of
time. We showed that the overall SMR of patients in the
observation cohort was lower than those in the ADT co-
hort in both age groups over the entire study period.
PCSM and mortality due to causes other than PCa were
lower in patients monitored with primary observation
compared to those managed with primary ADT. This
difference was particularly evident in patients aged 70–
79 years at the time of diagnosis. Overall survival was
also higher in subjects in this age group managed by pri-
mary observation. By contrast, a smaller difference in
PSCM was observed between patients undergoing ADT
and those managed by primary observation, while a clear
difference in mortality due to other causes was not seen
in patients aged 80 or older. This implies a better gen-
eral health condition and a healthier lifestyle among pa-
tients in the observation cohort.
An increased risk of PCSM was observed in patients
undergoing primary ADT compared to those managed
by primary observation, while a lower risk of other-cause
mortality was seen in the younger patient group man-
aged by primary observation. This suggests that in recent
times, primary ADT without curative treatment was
generally selected for patients with aggressive disease. A
10-year threefold risk of PCSM was associated with
poorly differentiated PCa among patients with conserva-
tively managed localized PCa in the Surveillance, Epi-
demiology, and End Results (SEER) Program [15]. Most
male patients with conservatively managed localized PCa
aged > 66 years with competing comorbidities died from
causes other than PCa in a period of 10 years, irrespect-
ive of age and tumor aggressiveness [16]. The use of pri-
mary ADT was beneficial for patients with aggressive
disease and few comorbidities [16]. However, overall
mortality was lower in subjects managed by observation
than with ADT. We assumed that a shift from ADT to a
more radical treatment may have occurred in patients
with a good general health status. Since an increasing
number of PCa cases has been diagnosed in recent years,
and observation is widely utilized in Finland, it is likely
that observation was selected for patients with less ag-
gressive histology and without advanced disease. Conse-
quently, fewer male patients died of cancer owing to the
slow, natural course of disease.
Overall survival was reduced in patients aged 70–79
years initially treated with. It is still difficult to draw a
Table 2 Overall mortality of the study patients compared to that of the male population of Finland
All patients Period
1985–1994 1995–2004 2005–2014
ADT Observation ADT Observation ADT Observation
Age SMR (95% confidence interval)
All (> 70) 1.48 (1.41–1.54) 1.20 (1.10–1.30) 1.19 (1.15–1.23) 1.03 (0.98–1.08) 1.08 (1.03–1.13) 0.93 (0.88–0.98)
70–79 1.57 (1.48–1.65) 1.17 (1.05–1.30) 1.24 (1.19–1.29) 1.05 (0.99–1.11) 1.11 (1.04–1.19) 0.95 (0.88–1.01)
≥80 1.39 (1.22–1.42) 1.25 (1.08–1.43) 1.10 (1.04–1.17) 1.00 (0.92–1.09) 1.04 (0.97–1.11) 0.89 (0.82–0.97)
Matched pairs
All (> 70) 1.50 (1.38–1.63) 1.19 (1.09–1.30) 1.19 (1.13–1.25) 1.03 (0.98–1.08) 1.09 (1.03–1.15) 0.93 (0.87–0.98)
70–79 1.57 (1.41–1.74) 1.16 (1.04–1.29) 1.23 (1.16–1.30) 1.05 (0.99–1.11) 1.12 (1.05–1.20) 0.94 (0.87–1.01)
≥ 80 1.39 (1.21–1.60) 1.25 (1.08–1.44) 1.12 (1.02–1.21) 1.00 (0.91–1.08) 1.03 (0.94–1.12) 0.91 (0.82–0.99)
Population mortality stratified by age and calendar year and education level
ADT androgen deprivation therapy, SMR standardized mortality ratio
Table 3 Risk of PCa and other-cause mortality among men on primary ADT compared to observation only
Time period (age) Relative risk of PCa mortality (95% CI) Relative risk of mortality due to causes other than PCa (95% CI)
ADT Observation ADT Observation
1985–1994 (70–79y) 1.70 (1.29–2.23) 1.00 (ref) 1.22 (1.00–1.49) 1.00 (ref)
1995–2004 1.55 (1.31–1.84) 1.00 (ref) 1.07 (0.97–1.18) 1.00 (ref)
2005–2014 2.71 (2.08–3.53) 1.00 (ref) 1.03 (0.92–1.16) 1.00 (ref)
1985–1994 (>80y) 1.30 (0.89–1.88) 1.00 (ref) 1.09 (0.85–1.39) 1.00 (ref)
1995–2004 1.49 (1.13–1.97) 1.00 (ref) 1.05 (0.92–1.20) 1.00 (ref)
2005–2014 1.65 (1.19–2.29) 1.00 (ref) 1.06 (0.91–1.23) 1.00 (ref)
p-value for age–period interaction = 0.237; p for age effect = 0.052; p for period effect = 0.005. Analysis is based on propensity matched pairs
PCa prostate cancer, CI confidence interval, ADT androgen deprivation therapy, ref. reference
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conclusion from this finding owing to the absence of
data on patient comorbidities. However, increased mor-
bidity and mortality from ADT-related side effects is
possible. Thus, the survival benefits of ADT are partly
offset by its high toxicity. These findings can also be ex-
plained by a better general health condition among pa-
tients in the observation group. In our cohort, patients
in the observation group had a clearly lower risk of over-
all mortality compared to patients undergoing primary
ADT. Since in epidemiological studies the only endpoint
that is free from bias is mortality, we can assume that
patients in observation cohort were healthier than those
in the ADT cohort.
Many population-based analyses suggest that
gonadotropin-releasing hormone (GnRH) agonist use is
associated with a greater risk of coronary artery disease,
myocardial infarction, and diabetes mellitus (DM) [17–
19]. Subsequent reports have suggested that male
patients with comorbidities or prior cardiovascular dis-
ease treated with GnRH agonists might be at increased
risk of cardiovascular mortality [20, 21]. Based on these
observations, a science advisory consensus statement on
GnRH agonist therapy and cardiovascular risk was is-
sued, together with a U.S. Food and Drug Administra-
tion safety warning to address concerns of increased risk
of myocardial infarction, stroke, sudden cardiac death,
and DM [22]. However, conflicting results have been re-
ported. In a recent meta-analysis, ADT use was not asso-
ciated with an increased risk of cardiovascular death, but
with a lower risk of PCSM and all-cause mortality [23].
Studer et al. also reported that ADT for localized PCa
may even reduce cardiovascular mortality if started im-
mediately after diagnosis [24].
The current study findings did not support the life-
prolonging effects of primary ADT for localized PCa.
Several reports have shown similar results: In a prior
Fig. 1 Overall survival among men aged 70–79 years and among men aged 80 or older
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population-based cohort study on 66,717 Medicare pa-
tients diagnosed between 1992 and 2009, and who re-
ceived no definitive local therapy within 180 days of
prostate cancer diagnosis, primary ADT was not associ-
ated with improved overall long-term CSS or the CSS of
patients with localized PCa [25]. Instead, there is evi-
dence that primary ADT led to inferior outcomes [24].
Low overall survival rates were reported for male pa-
tients with localized disease treated with primary ADT
rather than observation in a previous population-based
study [26]. In addition, Potosky et al. reported that pri-
mary ADT was neither associated with an enhanced risk
of all-cause mortality (hazard ratio [HR] of 1.04, 95% CI:
0.97–1.11) nor PCa-specific mortality (HR of 1.03; 95%
CI: 0.89–1.19) after adjusting for the sociodemographic
and clinical characteristics of patients with localized
PCa. However, primary ADT was associated with a de-
creased risk of all-cause mortality, but not PCSM,
among patients at high risk of PCa progression [27].
PSA screening practices have increased exponentially
over a 30-year period, and regular PSA testing is used
frequently among all socioeconomic groups in Scandi-
navia and Finland [28, 29]. In the early years of the
present study, a diagnosis of localized PCa was generally
performed via a digital rectal examination or using
pathological specimens obtained following a transureth-
ral resection of the prostate. In recent years, most local-
ized PCa cases have been diagnosed by prostate biopsies
prompted by elevated PSA values. Moreover, although a
proven benefit of the PSA screening of older males has
not been shown, PSA testing is frequently performed for
elderly patients [30]. The wide-stage migration of PCa
from advanced to indolent disease has been reported
over ≥20 years [31]. Thus, a commonly employed but
poorly organized screening policy explains the increased
rate of PCa in past decades in Finland. Consequently,
the number of elderly male patients with PCa has also
increased. This implies that the more favorable out-
comes associated with the use of primary observation
compared to ADT in patients with PCa, especially those
in their 70s, can be attributed to PSA-related “lead time”
rather than life extension.
Over the study period, staging of metastatic disease in
Finland was performed by bone scan examination ac-
cording to national guidelines until the mid-2000s, after
which low-risk PCa patients typically underwent no im-
aging. The proportion of de novo metastatic PCa in
Finland was nearly one-third from 1985 to 1994. This
implies that staging procedures of PCa by bone scans
were widely performed even in the earlier years of the
study period, suggesting a good quality of the TNM clas-
sification data of PCa in the Finnish Cancer Registry
database. In the Finnish Cancer Registry reports, the
proportion of de novo metastatic PCa has recently been
around 17%, higher than in Sweden [32], where the inci-
dence of PCa is high and PSA screening is widely per-
formed. This might also indicate a more aggressive PCa
histology in cases that are classified as localized by the
TNM system, and thus more commonly treated with im-
mediate ADT than cases with less aggressive histology.
A few points are worthy of further consideration. As
information on patient comorbidities and detailed PCa
characteristics (i.e., Gleason scores and PSA values) was
not collected, it was not possible to adjust for differences
in morbidity and mortality with a potential link to ADT.
Thus, a comparison of study outcomes in terms of
PCSM and overall survival between the different groups
was not possible. Also, due to the absence of data on pa-
tient comorbidities and PCa characteristics, it was not
possible to determine who would benefit from primary
ADT in localized PCa. However, propensity score
matching, particularly when applied to socioeconomic
status/education level, may have mitigated some of the
comorbidity-related limitations. Detailed information on
cancer treatment was also incomplete for both treatment
groups. Although men in the observation group did not
receive ADT or radical treatment in the four months fol-
lowing diagnosis, it is conceivable that some of them
may have received treatment later. This limitation may
have had a substantial effect on the study outcomes.
Furthermore, although the study population included
patients with localized PCa, the reliability of the staging
procedures over time is debatable. TNM staging was based
on mandatory reports obtained from hospitals and patho-
logical laboratories. In other words, clinical practices in
Finland were governed by national and/or European pros-
tate cancer guidelines of the time. Consequently, the risk of
metastases was evaluated according to these guidelines.
Notwithstanding these limitations, the study had several
strengths. It was an observational population-based study
estimating trends in cancer survival and mortality over
time. While we did not directly compare different types of
cancer treatments, population-based cohorts yield import-
ant information about PCa treatment in real-life situa-
tions, as the populations in randomized controlled trials
are selected using stringent criteria by excluding out sub-
stantial proportion of real-life patients. However, in
population-based studies patients are also allocated to dif-
ferent treatments, and results based on those can be sub-
ject to errors when comorbidities are involved. From an
epidemiological perspective, these data determine the
Finnish results obtained for patients managed with pri-
mary ADT or by observation. This study was based on na-
tionwide data for PCa and included nearly 100% of
patients in Finland over a nearly 30-year period. No previ-
ous population-based results from Finland on this subject
have been published. Similar complete population-based
coverage is not available in many European countries.
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Conclusion
Primary ADT within four months period from diagnosis
is not associated with improved long-term overall sur-
vival or decreased PCSM than primary conservative
management for men with localized PCa. However, the
study’s results may have been affected by patient selec-
tion or treatment intention as a consequence of general
health and healthcare service–related factors.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12894-020-00593-7.
Additional file 1: Table S1. Stage distribution of prostate cancer
patients by TNM-classification in Finland from 1985 to 2014.
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